Clinical trial
A Study of the Safety and Effectiveness of Risperidone for the Treatment of…
NCT00250354 · Janssen Pharmaceutica N.V., Belgium, Industry · Completed
Key facts
| NCT number | NCT00250354 |
|---|---|
| Title | A Study of the Safety and Effectiveness of Risperidone for the Treatment of Conduct Disorder and Other Disruptive Behavior Disorders in Children Ages 5 to 12 With Mild, Moderate, or Borderline Mental Retardation |
| Official title | The Safety And Efficacy Of Risperidone Versus Placebo In Conduct Disorder In Mild, Moderate And Borderline Mentally Retarded Children Aged 5 To 12 Years |
| Lead sponsor | Janssen Pharmaceutica N.V., Belgium, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Conduct Disorder, Oppositional Defiant Disorder, Disruptive Behavior Disorder |
| Intervention type | Drug |
| Interventions | Risperidone oral solution |
| Enrollment | 110 |
| Start date | Sep 1, 1997 |
| Completion | Aug 1, 1999 |
| First posted | Nov 8, 2005 |
| Last update posted | Jan 24, 2011 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: